Randomized, double-blinded, placebo controlled study of the effects of atomoxetine on cognitive function in patients with schizophrenia and normal controls based on COMT [catechol-O-methyl transferase] genotype.

Trial Profile

Randomized, double-blinded, placebo controlled study of the effects of atomoxetine on cognitive function in patients with schizophrenia and normal controls based on COMT [catechol-O-methyl transferase] genotype.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2013

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Schizophrenia
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 13 Jun 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 14 Dec 2011 Actual patient number is 11 according to ClinicalTrials.gov.
    • 14 Dec 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top